UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 72

Sortiert nach

Mechanism and non-mechanism based imaging biomarkers for assessing biological response to treatment in non-small cell lung cancer

European journal of cancer (1990), 2016-05, Vol.59, p.65-78

2016

Volltextzugriff (PDF)

Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer

Annals of oncology, 2013-05, Vol.24 (5), p.1416-1418

2013

Volltextzugriff (PDF)

Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or durvalumab in patients (pts) with advanced cancers

European journal of cancer (1990), 2016-12, Vol.69, p.S2-S2

2016

Volltextzugriff (PDF)

343 Translational phase I trial combining the AKT inhibitor AZD5363 (AZD) and PARP inhibitor Olaparib (Ola) in advanced cancer patients (pts)

European journal of cancer (1990), 2015-09, Vol.51, p.S68-S68

2015

Volltextzugriff (PDF)

67O Quantifying poly(ADP-Ribose) polymerase (PARP1) in vivo using a non-invasive PARP1 PET tracer

Annals of oncology, 2022-09, Vol.33, p.S572

2022

Volltextzugriff (PDF)

Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022

Annals of oncology, 2023-01, Vol.34 (1), p.48-60

2023

Volltextzugriff (PDF)

494TiP Phase Ib study of elimusertib (ATRi; BAY 1895344) in combination with niraparib (PARPi) in patients with advanced solid tumors

Annals of oncology, 2022-09, Vol.33, p.S767-S768

2022

Volltextzugriff (PDF)

Patient selection biomarker strategies for PARP inhibitor therapy

Annals of oncology, 2020-12, Vol.31 (12), p.1603-1605

2020

Volltextzugriff (PDF)

1258 POSTER Phase I Clinical Trial of a Genetically Modified Oncolytic Vaccinia Virus GL-ONC1 With Green Fluorescent Protein Imaging

European journal of cancer (1990), 2011, Vol.47, p.S162-S162

2011

Volltextzugriff (PDF)

682P Preclinical and ongoing phase I study data of the CHK1 inhibitor BBI-355 in development for patients with oncogene amplification on extrachromosomal DNA (ecDNA)

Annals of oncology, 2023-10, Vol.34, p.S477-S477

2023

Volltextzugriff (PDF)

19P Pharmacodynamic activity of [18F]-fluorthanatrace poly(ADP-ribose) polymerase (PARP) PET in BRCA1/2-mutated breast cancer patients receiving talazoparib

ESMO open, 2024-02, Vol.9, p.102350, Article 102350

2024

Volltextzugriff (PDF)

Defining the subset of mutations in polymerase epsilon (POLE) associated with loss-of-proofreading (LOP) functionality

Annals of oncology, 2024-07, Vol.35 (7), p.678-680

2024

Volltextzugriff (PDF)

HER2-low expression in patients with advanced or metastatic solid tumors

Annals of oncology, 2023-11, Vol.34 (11), p.1035-1046

2023

Volltextzugriff (PDF)

457MO A phase I study of ATR inhibitor M1774 in patients with solid tumours (DDRiver Solid Tumours 301): Part A1 results

Annals of oncology, 2022-09, Vol.33, p.S747-S748

2022

Volltextzugriff (PDF)

491TiP A first-in-human phase I/II study of BLU-222, a potent, selective CDK2 inhibitor in patients with CCNE1-amplified or CDK4/6 inhibitor-resistant advanced solid tumors

Annals of oncology, 2022-09, Vol.33, p.S765

2022

Volltextzugriff (PDF)

Challenges in combining novel molecularly targeted agents in cancer medicine

Annals of oncology, 2015-01, Vol.26 (1), p.9-11

Yap, T.A.

2015

Volltextzugriff (PDF)

713TiP A phase I study of PRT3789, a potent and selective degrader of SMARCA2 in patients with advanced or metastatic solid tumors and a SMARCA4 mutation

Annals of oncology, 2023-10, Vol.34, p.S493-S494

2023

Volltextzugriff (PDF)

1033TiP A first-in-human phase I study of FS120, an OX40/CD137 tetravalent bispecific antibody, in patients with advanced malignancies

Annals of oncology, 2021-09, Vol.32, p.S864-S865

2021

Volltextzugriff (PDF)

485P Correlation of clinical, genomic and hematological parameters with ATR inhibitor (ATRi) outcomes in phase I/II clinical trials

Annals of oncology, 2022-09, Vol.33, p.S761-S762

2022

Volltextzugriff (PDF)

424P MD Anderson Cancer Center global precision oncology decision support (Glo-PODS) clinical trial genomic support: Pilot program at the Prince of Wales Hospital (Chinese University of Hong Kong - CUHK)

Annals of oncology, 2023-11, Vol.34, p.S1629

2023

Volltextzugriff (PDF)

701P NCI10221: Phase II multicenter biomarker driven combination trial of copanlisib and nivolumab in patients with molecularly-selected advanced solid tumors (BaCoN)

Annals of oncology, 2023-10, Vol.34, p.S487-S488

2023

Volltextzugriff (PDF)

9P Preliminary population pharmacokinetic (popPK) co-variates and exposure response (ER) assessment of QT for RP-3500, a highly potent and specific inhibitor of ataxia telangiectasia and Rad3-related (ATR) protein kinase

Annals of oncology, 2022-03, Vol.33, p.S5-S6

2022

Volltextzugriff (PDF)

8P Pharmacokinetic (PK) profile and food effect of RP-3500, a highly potent and specific inhibitor of ataxia telangiectasia and Rad3-related (ATR) protein kinase in patients (pts) with cancer

Annals of oncology, 2022-03, Vol.33, p.S4-S5

2022

Volltextzugriff (PDF)

5MO Comprehensive dose-finding strategy for single-agent RP-3500, a highly selective inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase

Annals of oncology, 2022-03, Vol.33, p.S3-S4

2022

Volltextzugriff (PDF)

1 – 25 von 72

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(72)
Mit Volltextzugriff
(70)

Publikationsform

Artikel
(72)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(14)
Humans
(12)
Life Sciences & Biomedicine
(11)
Oncology
(9)
Female
(7)
Hematology, Oncology And Palliative Medicine
(6)
Male
(6)
Middle Aged
(5)
Aged
(4)
Adult
(3)
Antineoplastic Agents - Therapeutic Use
(3)
Biomarkers, Tumor - Metabolism
(3)
Cohort Studies
(3)
Neoplasms - Drug Therapy
(3)
Antineoplastic Agents - Adverse Effects
(2)
Disease Progression
(2)
Dose-Response Relationship, Drug
(2)
Immunohistochemistry
(2)
Immunotherapy
(2)
Phase I
(2)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Mechanism and non-mechanism based imaging biomarkers for assessing biological response to treatment in non-small cell lung cancer

Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer

Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or durvalumab in patients (pts) with advanced cancers

343 Translational phase I trial combining the AKT inhibitor AZD5363 (AZD) and PARP inhibitor Olaparib (Ola) in advanced cancer patients (pts)

67O Quantifying poly(ADP-Ribose) polymerase (PARP1) in vivo using a non-invasive PARP1 PET tracer

Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022

494TiP Phase Ib study of elimusertib (ATRi; BAY 1895344) in combination with niraparib (PARPi) in patients with advanced solid tumors

Patient selection biomarker strategies for PARP inhibitor therapy

1258 POSTER Phase I Clinical Trial of a Genetically Modified Oncolytic Vaccinia Virus GL-ONC1 With Green Fluorescent Protein Imaging

682P Preclinical and ongoing phase I study data of the CHK1 inhibitor BBI-355 in development for patients with oncogene amplification on extrachromosomal DNA (ecDNA)

19P Pharmacodynamic activity of [18F]-fluorthanatrace poly(ADP-ribose) polymerase (PARP) PET in BRCA1/2-mutated breast cancer patients receiving talazoparib

Defining the subset of mutations in polymerase epsilon (POLE) associated with loss-of-proofreading (LOP) functionality

HER2-low expression in patients with advanced or metastatic solid tumors

457MO A phase I study of ATR inhibitor M1774 in patients with solid tumours (DDRiver Solid Tumours 301): Part A1 results

491TiP A first-in-human phase I/II study of BLU-222, a potent, selective CDK2 inhibitor in patients with CCNE1-amplified or CDK4/6 inhibitor-resistant advanced solid tumors

Challenges in combining novel molecularly targeted agents in cancer medicine

713TiP A phase I study of PRT3789, a potent and selective degrader of SMARCA2 in patients with advanced or metastatic solid tumors and a SMARCA4 mutation

1033TiP A first-in-human phase I study of FS120, an OX40/CD137 tetravalent bispecific antibody, in patients with advanced malignancies

485P Correlation of clinical, genomic and hematological parameters with ATR inhibitor (ATRi) outcomes in phase I/II clinical trials

424P MD Anderson Cancer Center global precision oncology decision support (Glo-PODS) clinical trial genomic support: Pilot program at the Prince of Wales Hospital (Chinese University of Hong Kong - CUHK)

701P NCI10221: Phase II multicenter biomarker driven combination trial of copanlisib and nivolumab in patients with molecularly-selected advanced solid tumors (BaCoN)

9P Preliminary population pharmacokinetic (popPK) co-variates and exposure response (ER) assessment of QT for RP-3500, a highly potent and specific inhibitor of ataxia telangiectasia and Rad3-related (ATR) protein kinase

8P Pharmacokinetic (PK) profile and food effect of RP-3500, a highly potent and specific inhibitor of ataxia telangiectasia and Rad3-related (ATR) protein kinase in patients (pts) with cancer

5MO Comprehensive dose-finding strategy for single-agent RP-3500, a highly selective inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase

Suchergebnisse filtern